A single centre, double blind, randomised, parallel group, single dose signal study of R-107 in participants with DSM-5 specific phobia
A single centre, double blind, randomised, parallel group, single dose signal study of R-107 in particpants with DSM-5 specific phobia, to spiders.
Douglas Pharmaceuticals Ltd
12 participants
Sep 10, 2018
Interventional
Conditions
Summary
This is a single centre, double blind, randomised, parallel group, single-dose signal study of R-107 in participants with DSM-5 specific phobia to spiders. 12 participants will be randomised to receive a single dose of either R-107 or placebo. The hypothesis is that compared with placebo, R-107 will reduce anxiety self-ratings and avoidance behaviour associated with exposure to a phobic object (spider) in participants known to have a specific phobia according to DSM-5 criteria. Participants will complete several assesments prior to receiveing the dose, and then again 3 hours and 72 hours later.
Eligibility
Inclusion Criteria1
- Able to provide informed consent; able and willing to comply with study requirements including clinic visits; male or female (not pregnant or lactating); aged 18-40 years; BMI 18-35kg/m2; diagnosed with DSM-5 specific phobia to spiders for at least 12 months; able to swallow tablets; score >95 on Fear of Spiders questionnaire (at screening visit)
Exclusion Criteria1
- Clinically significant medical history or medications; clinically significant illness in last 30 days or febrile illness in last 5 days prior to Day 1; history of schizophrenia or other psychotic illness; currently taking benzodiazepines; prior exposure to ketamine; history of drug or alcohol abuse or dependency, including ketamine or it's excipients; clinically significant abnormal ECG or laboratory test result during screening; pregnant or breastfeeding female, or not using effective contraception; involvement in another clinical drug or device trial or less than 60 days since last participation; not having a GP or do not consent to GP being contacted; not able to understand information provided about the study, or not able to be compliant with required procedures; malignancy in last 5 years; employee/family member of sponsor, or study site.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will be administered a single dose of 120mg R-107 or matching placebo tablets. The dose will consist of 2 identical tablets, each tablet contains 60mg of R-107 (or placebo). Participants will be closely observed at the time of dosing and a mouth check will take place immediately after swallowing. Participants will take 240ml water with the dose. Tablets are to be swallowed whole, both at the same time. Participants will be dosed individually so each participant is closely observed.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12618001381279